PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders. The company is headquartered in South Plainfield, New Jersey.
| Revenue (TTM) | $1.01B |
| Gross Profit (TTM) | $503.96M |
| EBITDA | $171.22M |
| Operating Margin | 41.30% |
| Return on Equity | -7740.00% |
| Return on Assets | 2.46% |
| Revenue/Share (TTM) | $12.35 |
| Book Value | $-1.99 |
| Price-to-Book | 1743.27 |
| Price-to-Sales (TTM) | 4.90 |
| EV/Revenue | 3.639 |
| EV/EBITDA | 21.15 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 101.50% |
| Shares Outstanding | $83.46M |
| Float | $73.69M |
| % Insiders | 7.31% |
| % Institutions | 122.73% |
Volatility is currently expanding
WARREN, N.J., Oct. 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its third quarter 2026 financial results and provide a business update on Thursday, Oct. 29, 2026, at 4:30 p.m.
WARREN, N.J., Sept. 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept.
– Completion of BLA submission expected in Q4 2026 – WARREN, N.J., Sept. 21, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time administered AAV gene therapy for Fabry disease.
PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
WARREN, N.J., Aug. 27, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Wells Fargo 21st Annual Healthcare Conference Thursday, Sept.
– 17 abstracts and presentations planned at SSIEM Symposium – – Real-world evidence demonstrates significant diet liberalization achieved with Sephience while maintaining target blood Phe levels – – Continued evidence of meaningful benefit across all patient subgroups – WARREN, N.J., Aug. 24, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that multiple Sephience™ (sepiapterin) scientific data presentations will be featured at the 2026 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium, taking place in Helsinki, Finland, from Aug. 25-28.
PTC Therapeutics offers a compelling risk-reward profile, with its valuation not fully reflecting the upside from Sephience and potential ST-920 approval. Sephience, PTCT's lead asset, has driven rapid revenue growth, accounting for 63% of product revenue and expanding across major global markets. ST-920, acquired from Sangamo, is a late-stage gene therapy for Fabry Disease; FDA approval could significantly enhance PTCT's valuation.
PTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study Transcript
– Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization – – ST-920 is a one-time administered AAV gene therapy for the enzyme deficient in Fabry disease with demonstrated long-term clinical benefits and safety profile – – BLA submission expected to be completed in Q4 2026 with potential for commercial launch in 2027 – – PTC will host a conference call today, Aug. 12, at 5 p.m. ET – WARREN, N.J.
PTC Therapeutics (PTCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PTCT and any ticker you trade — then tracks every position and per-strategy win rate.
